Bleomycin Sulfate

製品コードS1214 別名：NSC125066

Bleomycin Sulfate化学構造

分子量(MW)：1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

サイズ 価格(税別)  
JPY 28220.00
JPY 111220.00
お問い合わせ バルク問合せ

文献中Selleckの製品使用例(6)

カスタマーフィードバック(1)

  • AACR 2011 Bleomycin Sulfate purchased from Selleck.

質量管理及び製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
体外試験

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLlNQKBmzFyMECg{txu MWCyOEBpyqB? MXXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NYfQVYE{OjZyOEi3NVE>
POLK WT M{n3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfuTWM2OD1zMT635qCKyrIkgJmxMlfDqM7:TR?= NFjlZ4czPjB|MUSwNC=>
POLK KO MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nTd2lEPTB;ND6wN-KBkcLz4pEJNU46OsLizszN MXSyOlA{OTRyMB?=
POLK CD MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHJdm5uUUN3ME21MlU66oDLwsJihKkyNjBywrFOwG0> MmLGNlYxOzF2MEC=
RLE/Abca3 NFuzeIZHfW6ldHnvckBCe3OjeR?= M33CSFAvPMLizszN NIW0eocyPDUEoHi= MVTpcoR2[2W|IHGgcY9zeGixbH;nbYNidCClaHHu[4Uh\nKxbTDldIl1cGWuaXHsMYxqc2VibX;ydIhwdG:peTD0c{BiKHerZHWsJJNxemWjZD3veZQhdW:{cHjvcI9ogcLi M3fGTVI2PzZyNUO4
PMCs M2C1bWZ2dmO2aX;uJGF{e2G7 MWiwMlHjiJN{wrFOwIcwdWx? MVeyOOKhcA>? NUfJWJFz[2G3c3XzJIEh\G:|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIIDyc5RmcW5ibHX2[Ywhd2ZiY3;scIFo\W5vSdMg MmXINlU2QTV4NEK=
PMCs NWT2U2NOTnWwY4Tpc44hSXO|YYm= NY\COJlTOC5{wrFOwIcwdWx? M{fkS|I16oDVN{NCpIg> MWPpcoR2[2W|IHnuZ5Jm[XOnczDpckB3cW2nboTpckBidmRizsGtV21CKHC{b4TlbY4> M3\4e|I2PTl3NkSy
PMCs MXXGeY5kfGmxbjDBd5NigQ>? NIrsXFAxNjMEoN88[{9udA>? NELoU2U4OiCq NGfubHlqdmS3Y3XzJIRm[3KnYYPld{BqdiCleYTvb4Vz[XSrbj24JIFv\CCHLXPh[IhmemmwIIDyc5RmcW5? M2jvflI2PTl3NkSy
PMCs NYfwe|B2TnWwY4Tpc44hSXO|YYm= NGL3[m4xNjMEoN88[{9udA>? MnvkNVIwOjRxNEigbC=> NH7PUYdqdmO{ZXHz[ZMh[2WubDDtbYdz[XSrb36= M3jL[lI2PTl3NkSy
IMR-32 NHz3WGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITSfJA4NjYkiKKxNlAhyrWpL33s M4nQfFEz6ojUNEigbC=> MYPJR|UxRTZyINM1[{9udCCjdDD0bIUh\W6mIH;mJFI1KGi{czDv[kBqdmO3YnH0bY9v NXLvbnFDOjV3M{[zOFU>
HT1080 NFqzS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLzNUDPxE1? MoqwNlQhcMLi M1fqdoxm[WS|IITvJIEhTzJxTTDk[YxigQ>? Mn24NlU2OTh7NkG=
HT1080 MUHGeY5kfGmxbjDBd5NigQ>? NGLkfZIyKM7:TR?= NFqyO3AzPCCqwrC= NXHrb|JHcW6mdXPld{BiKHCxdHXueEBodG:kYXygSG5CKGSjbXHn[UBz\XOyb37z[S=> MVSyOVUyQDl4MR?=
HDFn NFjPSmREgXSxdH;4bYNqfHliQYPzZZk> MmTWO|IhcA>? MmjoTWM2OD17LkOxKeKh M1LLc|I2Ojd4N{my
THP-1 M1;4dGN6fG:2b4jpZ4l1gSCDc4PhfS=> Mn3pO|IhcA>? M1O0cmlEPTB;ND63O{U> M4jJfVI2Ojd4N{my
HT-29 M2rROWN6fG:2b4jpZ4l1gSCDc4PhfS=> MnfEO|IhcA>? MYXJR|UxRTFzLkS5KS=> MlG4NlUzPzZ5OUK=
HCT116  M1y3SWN6fG:2b4jpZ4l1gSCDc4PhfS=> MnvtO|IhcA>? MYrJR|UxRTFzLkO0KS=> NUDiOWJqOjV{N{[3PVI>
A431 M1LTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXWRZE3PTBvMkCwJGlW MVi0PQKBkWh? MX;pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MoHBNlUyODF{OUm=
T24 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVu1NE0zODBiSWW= NUTQeIIzPDkkgJno M3j0d4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M{jJSFI2OTBzMkm5
AY-27  MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvNWnlWPTBvMkCwJGlW NHnMeFg1QOLCiXi= M1LD[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NGnyPZUzPTFyMUK5PS=>
A549 NULifVU3TnWwY4Tpc44hSXO|YYm= M2TPS|EhyrWpL33MxsA> M4LZNlAuPDhiaB?= M1y5R4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[uKhV1CQwrDtVm5C Ml[yNlQ6PjN4M{W=
MLE12 MoPwSpVv[3Srb36gRZN{[Xl? M4\uWFEhyrWpL33MxsA> MYOwMVQ5KGh? MofWbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBQWE8EoH3SUmE> NYjXNoxSOjR7NkO2N|U>
Jurkat NXfnbJc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljlNlDjiIoQvH2= M2\1blI16oDLaNMg MofRZZJz\XO2czD0bIUh[2WubDDjfYNt\SCjdDD0bIUhTzJicHjhd4U> NIrYNmMzPDlzNki5Ny=>
HeLa  NIfFe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDqcGI4UUN3ME2xNE4zyqEQvF2= NF3mXVkzPDd|MkO5Oy=>
C18-4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkmyNE0yODBizszN Mn\6bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NWDm[pY3OjR3N{G5PFI>
BMG-1  NFO1V|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjqWJgxPDBxOEFCpO69\y:v MXmzxsBp MmPWbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MmLTNlM6ODZ5Mk[=
A459 M2rib2Fxd3C2b4Ppd{BCe3OjeR?= MkTBNVAhdVV? MXq0PEBp MYHpcoR2[2W|IHHwc5B1d3Orcx?= MUmyN|kxOjd4Nh?=
MOCK M4XGSWFxd3C2b4Ppd{BCe3OjeR?= M3W4SFExKG2X M3S5NFQ5KGh? MWnpcoR2[2W|IHHwc5B1d3Orcx?= M4KzdlI{QTB{N{[2
MMP1 NHzYemFCeG:ydH;zbZMhSXO|YYm= NVXuSHA{OTBibWW= M3fEN|Q5KGh? MlvWbY5lfWOnczDhdI9xfG:|aYO= Ml\oNlM6ODJ5Nk[=
A549 NV\iO5lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL2eHBsOjByIN88US=> M1vZelI1KGkEoB?= NYe5UWdm\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NGPCT2IzOzhyNUe5Ny=>
HCT-116 Mn3FRZBweHSxc3nzJGF{e2G7 MoTIN{84NjVxMUWg{txoN22u NF\QeYU1QCCq NYHGSY5iemWmdXPld{B1cGVibHX2[Ywhd2ZiQlzIJIF1KGirZ3igZ49v[2WwdILheIlwdg>? MVmyN|cxQDZ4OB?=
HeLa NVj4eZhWSXCxcITvd4l{KEG|c3H5 NGDlZZM{NzdwNT:xOUDPxGdxbXy= Mo[3OFghcA>? M1\BZpJm\HWlZYOgeIhmKGyndnXsJI9nKEKOSDDheEBpcWeqIHPvcoNmdnS{YYTpc44> MmTVNlM4ODh4Nki=
HCT116 NUHOWnlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7GNE0yODBizsznM41t NXK2eZZQPDhiaB?= M1P5O4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NF;SUmgzOzVzOEKwNS=>
NCM460 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XBXFAuOTByIN88[{9udA>? MV20PEBp MX\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MmXONlM2OTh{MEG=
NT2  M3TtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnnVFZnOjRiaNMg MV3MSFUxRTRyMPMAjeK2\y:vbB?= MmnkNlM{QDZ2MkC=
NT2  MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jYd|Q5KGh? NF[zPYxNTDVyPUGwNEDDvWdxbXy= NXz0coh5OjN|OE[0NlA>
NT2  M2fzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVK3NkBp NGO5d4xNTDVyPUKw5qCKyrWpL33s NIe0WoozOzN6NkSyNC=>
NT2  MXzBdI9xfG:|aYOgRZN{[Xl? NUHLXW0xPDBy4pEJxtVoN22u MVOyOEBpyqB? NUHlNmFYcW6mdXPld{B{cWewaX\pZ4FvfCCrbnPy[YF{\XNiaX6gZ4F{eGG|ZT2zMFgtQSCjY4Tpeol1gcLi Mm\wNlM{QDZ2MkC=
NTera-2 M{i0UWZ2dmO2aX;uJGF{e2G7 M2\NVFEzOCEQvHevcYw> MVm3NkBp M3vKNpNq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz NYfCXpZWOjJ6MkWzOVU>
NCCIT MVjGeY5kfGmxbjDBd5NigQ>? NIf0RmgyOjBizsznM41t M{naNFczKGh? MlvWd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiOD3pd49xem:|dHHu[UBt\X[nbIO= MV[yNlgzPTN3NR?=
NTera-2 NHzyPHRHfW6ldHnvckBCe3OjeR?= M{nEeVEzOCEQvHevcYw> NHXZWXo4OiCq NWfvXmdVe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ NHvhO4czOjh{NUO1OS=>
NCCIT M3fSN2Z2dmO2aX;uJGF{e2G7 MoDnNVIxKM7:Zz;tcC=> NHvrPWU4OiCq MX7zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCWQlHSV{Bt\X[nbIO= MkHHNlI5OjV|NUW=
NCCIT MV\GeY5kfGmxbjDBd5NigQ>? MUSxNlAh|rypL33s MmjNO|IhcA>? MnrDd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiR2PIJIxmfmWucx?= MnKxNlI5OjV|NUW=
NTera-2 NHTiXW9HfW6ldHnvckBCe3OjeR?= MYixNlAh|rypL33s NHXvfYw4OiCq NIq0dJZ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDQdo91\WmwIHPhdoJwdnmuIHzleoVtew>? NITDNnczOjh{NUO1OS=>
NCCIT M3yyb2Z2dmO2aX;uJGF{e2G7 MlrxNVIxKM7:Zz;tcC=> MnGyO|IhcA>? NXW4WJdne2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgVJJwfGWrbjDjZZJjd267bDDs[ZZmdHN? NYXV[mhlOjJ6MkWzOVU>
NTera-2 M3fKRWZ2dmO2aX;uJGF{e2G7 M1vmR|EzOCEQvHevcYw> Mnq5O|IhcA>? MnrLd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiTGDPJIxmfmWucx?= MYiyNlgzPTN3NR?=
NCCIT M2P6NGZ2dmO2aX;uJGF{e2G7 M{LYeFEzOCEQvHevcYw> NEn0Vnc4OiCq MU\zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCOUF:gcIV3\Wy| M{e0WFIzQDJ3M{W1
MDA-MB-468 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkOwNQKBmzJyMNMg{txoN22O M4S2flI1KGh? MoTmbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NIC0SoEzOjhzOUG5Oi=>
231-H2N NGO1[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWqzcZdTOOLCk{KwNOKh|rypL33M MkDONlQhcA>? MWXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MlHONlI5OTlzOU[=
A549  MmjQSpVv[3Srb36gRZN{[Xl? NWXHTIVIOjByL{SwNEDPxE1? M2m1Z5Jme3WudIOgbY4h[SCmb4PlMZJme3CxboPpeoUhcW6lcnXhd4UhcW5iUl;T NYrDO2xUOjJ5N{O2PVc>
A549  NHfzSINHfW6ldHnvckBCe3OjeR?= M1Tu[lAuPDByIN88US=> MkPuNk01QCCq NYjwfZZi[2G3c3XzJI1wemVibYTEUmEhfGijbjDuSG5CKGSjbXHn[S=> NWPaT3NJOjJ5N{O2PVc>
A549  MUDGeY5kfGmxbjDBd5NigQ>? M1iwU|ExOCEQvF5CpC=> MX:w5qCUPDhiaB?= MVrjZZV{\XNiY3HzdIF{\S1|IHHjeIl3[XSrb36= NEC5W4gzOjd5M{[5Oy=>
A549  M2DmNGZ2dmO2aX;uJGF{e2G7 MUmxNFAh|ryPwrC= MXmw5qCUPDhiaB?= MX7jZZV{\XNiUFvENUBkdGWjdnHn[S=> NWOy[pdYOjJ5N{O2PVc>
A549  MUHGeY5kfGmxbjDBd5NigQ>? M12wXFExOCEQvF5CpC=> MlfPNQKBmzR6IHi= M1nIc4NifXOnczDtbZRw[2ixbnTybYFtKGyxY3HsbZpifGmxbjDv[kBD[Xh? M4PnRlIzPzd|Nkm3
A549  NIi5WJJHfW6ldHnvckBCe3OjeR?= NFfhWWQyODBizszNxsA> MmTXNQKBmzR6IHi= Mn71[IVkemWjc3XzJG1OWCCjbnSgRXRRKGyndnXsdy=> NH:yVm4zOjd5M{[5Oy=>
MCF-7/Her-18  NUnkZ3hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7iNE41Oi1zN{CwJO69\y:vTB?= MkHHNlQhcA>? NH3ne2RqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MoLXNlI3OjF2MES=
MCF-7 M1q5TnBFXC:SQ1mgWJJm[XSvZX70 M4HheFAvOjVizsznM41tNg>? NEnGN4wyNTRiaB?= NH:xcXp{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 NEf4e3AzOjV7MUK4OC=>
MDA-MB-231 NUT5UXAxWESWL2DDTUBVemWjdH3lcpQ> NV2zOIpUOC5{NTFOwIcwdWxw M2\H[lEuPCCq M1LldpNpd3e|IIPp[45q\mmlYX70JEhRyqB:IECuNFUqKGO7dH;0c5hq[yCnZn\lZ5Q> MnTINlI2QTF{OES=
MDA-MB-235  Mlm2VGRVN1CFSTDUdoVifG2nboS= NY\KeJB4OC5{NTFOwIcwdWxw MoC3NU01KGh? M3\VPJNpd3e|IIPp[45q\mmlYX70JEhRyqB:IECuNFUqKGO7dH;0c5hq[yCnZn\lZ5Q> M3HpRVIzPTlzMki0
MCF-7 NXv4ZnBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTVeIt{OC1{IN88[{9udC5? MVSyOE81QCCq NI[3Zm9GSzVyPUGuNkDPxGdxbVy= MV2yNlU6OTJ6NB?=
NCCIT  MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof4NlDjiJNzNEFCpO69\y:vbB?= MVW3NkBp NIjFZ3NNTDVyPUGyNOKh|rypL33sxsA> MXiyNlU3OjF4MB?=
NCCIT  NIm3O2pHfW6ldHnvckBCe3OjeR?= MXi3NkBp MVrzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNTNiYXP0bZZqfHoEoB?= M4j5UVIzPTZ{MU[w
NCCIT  M4HuXWZ2dmO2aX;uJGF{e2G7 Mo\wO|IhcA>? MoLGd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S16IHHjeIl3cXS7wrC= MXKyNlU3OjF4MB?=
NCCIT  NWDtUmNrTnWwY4Tpc44hSXO|YYm= M3mwSlczKGh? Mljrd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S17IHHjeIl3cXS7wrC= MmWwNlI2PjJzNkC=
NCCIT  MX3GeY5kfGmxbjDBd5NigQ>? M4HyU|czKGh? M1fHbJNq\26rZnnjZY51dHliaX7jdoVie2W|IFLBXEBt\X[nbB?= NWLU[4hsOjJ3NkKxOlA>
NCCIT  M3jqPGZ2dmO2aX;uJGF{e2G7 NW\iV5RTPzJiaB?= NFPO[pB{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUhSmOuLUKgZ49vfGWwdB?= NFTCUWwzOjV4MkG2NC=>
NCCIT  NI\lRm5HfW6ldHnvckBCe3OjeR?= M3raclczKGh? NV7wOZFMe2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKEO7dD3jJIxmfmWu M3HUelIzPTZ{MU[w
HeLa NHTQfJFHfW6ldHnvckBCe3OjeR?= NIPJdok{OC95MDFOwIcwdWx? M{OxdlI1yqCq M2XZ[olv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqHB3M,-8kGFVVSyyMkJCpIFv\MLiR1HESFQ2 M3;YNFIzPDh5OUO3
MCF-7  Mo\XSpVv[3Srb36gRZN{[Xl? NH7kT3E{OC95MDFOwIcwdWx? M1X1U|I1yqCq M3T2Wolv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqHB3M,-8kGFVVSyyMkJCpIFv\MLiR1HESFQ2 NWTlVoFEOjJ2OEe5N|c>
HeLa NH7Te|FEgXSxdH;4bYNqfHliQYPzZZk> MoP1N|AwPzBizsznM41t M1jVXlI1yqCq MoLZbY5lfWOnczDobYdpdHlic3nncolncWOjboSgcIV3\Wy|IH;mJIZz[WevZX70[YQhTE6DIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOv NH3ZUGEzOjR6N{mzOy=>
MCF-7  NGC3bW1EgXSxdH;4bYNqfHliQYPzZZk> MoX6N|AwPzBizsznM41t MoLENlTDqGh? NXvBTYtDcW6mdXPld{BpcWeqbImgd4lodmmoaXPhcpQhdGW4ZXzzJI9nKG[{YXft[Y51\WRiRF7BJJJmdGWjc3WgbY51dyC2aHWgZ5l1d3CuYYPt NULiUZl5OjJ2OEe5N|c>
NT2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TydVExOC14MEFCpO69\y:vbB?= MU[yOEBp NXPhOlViUUN3ME20NFAhyrWpL33s NYf4OGZlOjJ2Nkm5OVI>
NT2 MXzGeY5kfGmxbjDBd5NigQ>? MmnVOFAxyqEQvHevcYw> MnLvNlQhcA>? NETOWG9{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUOsPEw6KGGldHn2bZR6yqB? M4nWelIzPDZ7OUWy
NT2 MX3GeY5kfGmxbjDBd5NigQ>? M3znRVQxOMLizsznM41t NVe1[HVIOjRiaB?= NYPXOIs6e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgRmFZKGyndnXs MX6yNlQ3QTl3Mh?=
NT2 M{HQZ2Z2dmO2aX;uJGF{e2G7 NVHGTVNHPDBywrFOwIcwdWx? Mlz4NlQhcA>? NWfKWoZ[e2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgRoNtNTJibHX2[Yw> NInLcYMzOjR4OUm1Ni=>
CHO NIXtdZlHfW6ldHnvckBCe3OjeR?= M{G0XVIvPcLizsznM41t MnTtNVghcC94IHS= MXPpcoR2[2W|wrDw[ZJ{cXO2ZX7j[UBw\iClaILvcY9{d22nIHThcYFo\Q>? NX\FcpJYOjJ{M{CxPVU>
Jurkat MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDnXZNuOC1zMEFCpO69\y:vbB?= MmG5NlQhcA>? NUPxbXNT[XK{ZYP0d{B1cGViY3XscEBkgWOuZTDheEB1cGViR{KgdIhie2V? NVXGZnpDOjJ{MkOzN|I>
Jurkat NHW1WFFHfW6ldHnvckBCe3OjeR?= M3vCR|MxyqEQvHevcYw> MVyyOEBp MmK5bY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCleXPsbY5{KER|LDDBJIFv\CCEMR?= MlzjNlIzOjN|M{K=
Jurkat NE\remhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDMNE0yODEEoN88[{9udA>? NGrBeIozPCCq MXvpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKge4l1cCCjbjDJR|UxKH[jbIXlJI9nKDFyMN88[{9uVA>? NULKbIF2OjJ{MkOzN|I>
Jurkat M4q1TWZ2dmO2aX;uJGF{e2G7 MUKzNOKh|rypL33s MXiyOEBp M3\4cIlv[3KnYYPld{B1cGViZX\m[YN1KG:oIID5Z45q\GmxbnWgc44heGixc4Doc5J6dGG2aX;uJIxmfmWuczDv[kBpcXO2b37lJGgzSS6[ M4X2elIzOjJ|M{Oy
U2OS EGFPnls NEDJZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzXPIRTOC1{wrFOwIcwdWx? NYfO[VVVOjRiaB?= M37WWYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M{XQOFIyQDFzMEC3
U2OS KuEnls NXXMV|U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nkVVAuOsLizsznM41t M2jjbVI1KGh? MWPpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 Mn\GNlE5OTFyMEe=
MCF-7 NUfGNG5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDkdGgxNTRyMDFOwG0> NGnmSJc4OiCq NV7yS3M3VEN3ME2xOVEvQMLizszN Mom5NlE4ODN{OUG=
MCF-7/Adr  MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;VeJcxNTRyMDFOwG0> NEG1WnQ4OiCq NYDpWotwVEN3ME21PE42yqEQvF5CpC=> MlznNlE4ODN{OUG=
WI-38 MmXsSpVv[3Srb36gRZN{[Xl? MWGwM|QxNzhy4pEJ{txoN22uwrC= MYSzJIg> MXnpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg M3LTRlIyPTl7NkGy
hBMSC MWDGeY5kfGmxbjDBd5NigQ>? MVKwM|QxNzhy4pEJ{txoN22uwrC= MnnvN{Bp MlnWbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> M{jjZlIyPTl7NkGy
NCI-H23 NGHW[4pHfW6ldHnvckBCe3OjeR?= M3zGXFAwPDBxOEFihKnPxGdxbX|CpC=> NXj5R2NNOyCq Mlu0bY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> MYKyNVU6QTZzMh?=
A-549 M1;n[2Z2dmO2aX;uJGF{e2G7 MXmwM|QxNzhy4pEJ{txoN22uwrC= NFLIc3U{KGh? NW[2b3k1cW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? MUKyNVU6QTZzMh?=
PBL  MnjzSpVv[3Srb36gRZN{[Xl? M3jSd|AwPDBxOEFihKnPxGdxbX|CpC=> Mo\zN{Bp MVzpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg NX:5S3FlOjF3OUm2NVI>
pol β −/− M{\xNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDV[osxNjJ3LUKwNOKh|rypL33s MkHuNlTDqGh? NWHTSm5Y\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li NXe1cWhYOjF{NUG5OFQ>
pol β +/+ MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjzUXQxNjJ3LUKwNOKh|rypL33s M1e4UVI1yqCq MV3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3n0bEBqdmO{ZXHzbY5oKGOxbnPlcpRz[XSrb37zxsA> NWnmenZiOjF{NUG5OFQ>
pol β −/− NX\U[3BKTnWwY4Tpc44hSXO|YYm= NH6xPJExNTJwNTFOwIcwdWx? MYWyJIg> NX3DepRV[2G3c3XzJGRPSSCmYX3h[4U> NV3nXoViOjF{NUG5OFQ>
pol β +/+ MXHGeY5kfGmxbjDBd5NigQ>? NF7DRmkxNTJwNTFOwIcwdWx? M1nPclIhcA>? NVSyR4Vt[2G3c3XzJGRPSSCmYX3h[4U> MVmyNVI2OTl2NB?=
pol β −/− NIjFcVRHfW6ldHnvckBCe3OjeR?= M{LMbFAuPSEQvHevcYw> MnnqOFghcA>? NEnmOHRk[XW|ZYOgcYlkem:wdXPs[ZV{KGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> Mn3hNlEzPTF7NES=
pol β +/+ MWHGeY5kfGmxbjDBd5NigQ>? NGfnblIxNTVizsznM41t M1[5N|Q5KGh? MnPJZ4F2e2W|IH3pZ5JwdnWlbHX1d{Bld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 MnfRNlEzPTF7NES=
TK6  M1PFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\iflMzPS1zNUCg{txoN22u MXK5OkBp MmHQbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NWHlOpU2OjFyOEG0PFc>
TK6  sLUC+Apn1 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP5c49XOjVvMUWwJO69\y:vbB?= NE\MOos6PiCq NFvDW5NqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MV2yNVA5OTR6Nx?=
TK6 sAPE1+Apn1 M1TjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3jWlNLOjVvMUWwJO69\y:vbB?= MYG5OkBp NIflXWp{cWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= M4XVTVIyODhzNEi3
HCT116 NFvhfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFWzcFkzPS1zNUCg{txoN22u NVH2blBvQTZiaB?= MV\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MnvCNlExQDF2OEe=
HCT116 sLUC+Apn1 NVrvOpVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyyOU0yPTBizsznM41t NFTYXlg6PiCq MYHpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NGeyNHIzOTB6MUS4Oy=>
HCT116 sAPE1+Apn1 NWP1enV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfpPYw{OjVvMUWwJO69\y:vbB?= M2ntN|k3KGh? MVzzbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHyg[5Jwf3SqIHTvd4Uh\GWyZX7k[Y51dHl? NHuxVmozOTB6MUS4Oy=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい
体内試験 Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

お薦めの試験操作（参考用のみ）

細胞試験：

[4]
+ 展開
  • 細胞株： ADIPO-P2 cells
  • 濃度： 2.5 μg/mL
  • 反応時間： 30 minutes
  • 実験の流れ：

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (参考用のみ)
動物試験：

[7]
+ 展開
  • 動物モデル： CD-1 mice
  • 製剤： Saline
  • 投薬量： 5 mg/kg, 2 ml/kg
  • 投与方法： Administered via i.t.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (66.11 mM) warming
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
体内 左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
Saline
混合させたのち直ちに使用することを推奨します。 		30 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 1512.62
化学式

C55H85N17O25S4
CAS No. 9041-93-4
保管 粉
in solvent
別名 NSC125066

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 8 2010 Phase 2
NCT00983944 Withdrawn Lymphoma Ohio State University Comprehensive Cancer Center September 2009 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • 回答：

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

selleck catalog

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • YK-4-279

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • BMH-21

    BMH-21 is a DNA intercalator, which binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription.

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Gemcitabine

    Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

  • Fluorouracil (5-Fluoracil, 5-FU)

    Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

Tags: Bleomycin Sulfateを買う | Bleomycin Sulfate ic50 | Bleomycin Sulfate供給者 | Bleomycin Sulfateを購入する | Bleomycin Sulfate費用 | Bleomycin Sulfate生産者 | オーダーBleomycin Sulfate | Bleomycin Sulfate化学構造 | Bleomycin Sulfate分子量 | Bleomycin Sulfate代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID